← Back to Clinical Trials
Recruiting NCT07073209

NCT07073209 PENG vs Femoral Block for Hip Fracture Analgesia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07073209
Status Recruiting
Phase
Sponsor Weill Medical College of Cornell University
Condition Hip Fractures
Study Type INTERVENTIONAL
Enrollment 352 participants
Start Date 2025-07-10
Primary Completion 2027-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
PENG Block AdministrationFemoral Block AdministrationBupivacaine , epinephrine Dexamethasone

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 352 participants in total. It began in 2025-07-10 with a primary completion date of 2027-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the Pericapsular Nerve Group (PENG) block with femoral block for hip fracture pain. Participants presenting to the hospital with a diagnosis of hip fracture and consenting to analgesic block will receive either a PENG or femoral block. The choice of block will be dictated by a randomized monthly schedule, and all participants presenting during each four-week period will receive the designated block. A sub-group analysis will be performed to determine any difference in efficacy in participants with intracapsular versus extracapsular fractures.

Eligibility Criteria

Inclusion Criteria: 1. Male or female ≥ 18 years of age. 2. ASA Classification 1-4 3. Documentation of a hip fracture diagnosis along with radiologic read indicating fracture location 4. Written, informed consent for analgesic peripheral block placement Exclusion Criteria: 1. Altered mental status to the extent that it limits ability to report pain score 2. Patient or health care proxy refusal of analgesic nerve block 3. Allergy to study medications or contraindication to peripheral nerve block 4. Peri-prosthetic fracture 5. Any additional fractures in a patient with a unilateral hip fracture

Contact & Investigator

Central Contact

Michele Steinkamp, BSN, RN

✉ mls9004@med.cornell.edu

📞 212-746-2953

Principal Investigator

Tiffany Tedore, MD

PRINCIPAL INVESTIGATOR

Weill Medical College of Cornell University

Frequently Asked Questions

Who can join the NCT07073209 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hip Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07073209 currently recruiting?

Yes, NCT07073209 is actively recruiting participants. Contact the research team at mls9004@med.cornell.edu for enrollment information.

Where is the NCT07073209 trial being conducted?

This trial is being conducted at Manhattan, United States.

Who is sponsoring the NCT07073209 clinical trial?

NCT07073209 is sponsored by Weill Medical College of Cornell University. The principal investigator is Tiffany Tedore, MD at Weill Medical College of Cornell University. The trial plans to enroll 352 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology